Cargando…

Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment

Immune checkpoint inhibitors and tyrosine kinase inhibitors are the first-line treatment for metastatic renal cell carcinoma (mRCC), but their benefits are limited to specific patient subsets. Here, we aimed to evaluate the therapeutic efficacy of JX-594 (pexastimogene devacirepvec, Pexa-vec) monoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Jee Soo, Lee, Myung Eun, Jang, Won Sik, Kim, Jongchan, Park, Se Mi, Oh, Keunhee, Lee, Namhee, Ham, Won Sik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773601/ https://www.ncbi.nlm.nih.gov/pubmed/35052851 http://dx.doi.org/10.3390/biomedicines10010173

Ejemplares similares

The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer
por: Kim, Jongchan, et al.
Publicado: (2017)

Is the extirpative surgery for primary tumor helpful for the patients with metastatic urothelial cancer at the time of diagnosis?
por: Kim, Jongchan, et al.
Publicado: (2019)

Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers
por: Park, Jee Soo, et al.
Publicado: (2022)

Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies
por: Lee, Namhee, et al.
Publicado: (2023)

Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes
por: Lou, Jiaying, et al.
Publicado: (2021)

Remodeling of Tumor Immune Microenvironment by Oncolytic Viruses
por: Zhang, Bin, et al.
Publicado: (2021)

Correction: Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes
Publicado: (2022)

Oncolytic Vaccinia Virus Augments T Cell Factor 1-Positive Stem-like CD8(+) T Cells, Which Underlies the Efficacy of Anti-PD-1 Combination Immunotherapy
por: Jeon, Yun-Hui, et al.
Publicado: (2022)

Risk Prediction Tool for Aggressive Tumors in Clinical T1 Stage Clear Cell Renal Cell Carcinoma Using Molecular Biomarkers
por: Park, Jee Soo, et al.
Publicado: (2019)

Nephron-Sparing Approaches in Upper Tract Urothelial Carcinoma: Current and Future Strategies
por: Ham, Won Sik, et al.
Publicado: (2022)

Development of a highly pulmonary metastatic orthotopic renal cell carcinoma murine model
por: Park, Jee Soo, et al.
Publicado: (2021)

Remodeling the tumor immune microenvironment with oncolytic viruses expressing miRNAs
por: St-Cyr, Guillaume, et al.
Publicado: (2023)

Prognostic value of prostate volume in non-muscle invasive bladder cancer
por: Ham, Won Sik, et al.
Publicado: (2021)

Recent global trends in testicular cancer incidence and mortality
por: Park, Jee Soo, et al.
Publicado: (2018)

Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment
por: Fend, Laetitia, et al.
Publicado: (2015)

Association between visceral adiposity and DDX11 as a predictor of aggressiveness of small clear-cell renal-cell carcinoma: a prospective clinical trial
por: Park, Jee Soo, et al.
Publicado: (2021)

Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment
por: Wang, Lihong, et al.
Publicado: (2022)

Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade
por: Inoue, Mitsuko, et al.
Publicado: (2021)

The Addition of Recombinant Vaccinia HER2/neu to Oncolytic Vaccinia-GMCSF Given into the Tumor Microenvironment Overcomes MDSC-Mediated Immune Escape and Systemic Anergy
por: de Vries, Christiaan R., et al.
Publicado: (2015)

Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors
por: Béguin, Jérémy, et al.
Publicado: (2023)

Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models
por: Cecil, Alexander, et al.
Publicado: (2019)

Apoptin enhances the oncolytic properties of vaccinia virus and modifies mechanisms of tumor regression
por: Kochneva, Galina, et al.
Publicado: (2014)

Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation
por: Chen, Lingjuan, et al.
Publicado: (2021)

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
por: Minev, Boris, et al.
Publicado: (2014)

Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy
por: Kochneva, Galina, et al.
Publicado: (2016)

Theranostic Potential of Oncolytic Vaccinia Virus
por: Rojas, Juan J, et al.
Publicado: (2012)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

Oncolytic properties of non-vaccinia poxviruses
por: Ricordel, Marine, et al.
Publicado: (2018)

Management of postoperative ileus after robot-assisted laparoscopic prostatectomy
por: Park, Jee Soo, et al.
Publicado: (2018)

Predictive value of preoperative monocyte–lymphocyte ratio among patients with localized clear renal cell carcinoma of ≤7 cm on preoperative imaging
por: Elghiaty, Ahmed, et al.
Publicado: (2018)

Neutrophil-to-Lymphocyte Ratio Predicts Pathological Renal Sinus Fat Invasion in Renal Cell Carcinomas of ≤7 cm with Presumed Renal Sinus Fat Invasion
por: Kim, Jongchan, et al.
Publicado: (2019)

Outcomes of pathologically localized high-grade prostate cancer treated with radical prostatectomy
por: Heo, Ji Eun, et al.
Publicado: (2019)

The DEAD/DEAH Box Helicase, DDX11, Is Essential for the Survival of Advanced Clear Cell Renal Cell Carcinoma and Is a Determinant of PARP Inhibitor Sensitivity
por: Park, Jee Soo, et al.
Publicado: (2021)

Prediction of High-Grade Clear Cell Renal Cell Carcinoma Based on Plasma mRNA Profiles in Patients with Localized Pathologic T1N0M0 Stage Disease
por: Park, Jee Soo, et al.
Publicado: (2020)

Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009)

Oncolytic Vaccinia Virus in Lung Cancer Vaccines
por: Truong, Cao-Sang, et al.
Publicado: (2022)

Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells
por: Kilinc, Mehmet Okyay, et al.
Publicado: (2016)

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice
por: Gil, M, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8steoaocol42df7pmlcd2ci2mn